key: cord-0846721-a4hxle3v
authors: Curran NursD, Evonne T.
title: Airborne or Droplet – is it possible to say?
date: 2020-08-29
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2020.08.022
sha: 5cf971b5f457e8a05ed2cc547cd5832db17403d0
doc_id: 846721
cord_uid: a4hxle3v

nan

It had been assumed that we could, through the identification of a pathogen and / or procedure, accurately categorise airborne pathogens from those transmitted via droplets. For SARS-CoV-2 the main routes of transmission are via droplets and contact 1 . There is an increased risk of airborne transmission under certain conditions. Airborne transmission necessitates airborne precautions, i.e. healthcare workers (HCWs) are required to use FFP3 masks, whereas for droplet transmission a fluid-repellent surgical face mask will suffice to protect the mouth and nose (additional eye protection being required) 1 . The terminology in national guidance was familiar to infection prevention and control teams (IPCTs) but was unfamiliar to clinicians and created confusion. Investigations reveal the basis for classifying respiratory transmission is perhaps over-interpreted.

The term 'Aerosol-Generating Procedures' (AGPs), used to differentiate when airborne-transmission could arise, provoked uncertainty. Firstly, the term 'aerosol' has multiple definitions, e.g. a perfume spray creates aerosols.

Guidance defines aerosols as small, neutrally buoyant, and thus able to remain suspended in the air over both long periods and distances 2 . Evaporated larger droplets termed 'droplet nuclei' also result in airborne transmission. Another review states that: "aerosolised disease transmission can be classified as either droplet or airborne" 3 . Ergo, as droplets are also aerosols, it is understandable that using the term 'AGPs' caused confusion -the term lacks specificity. The listed AGPs were devised from literature reviews which evaluated evidence largely from outbreak reports 4 . However, unlike other coronaviruses, SARS-CoV-2 is reported to replicate throughout the respiratory tract 5 -which may explain some of the high-transmissibility. It also raises questions about the validity of extrapolating data from reports of pathogens with lower transmissibility and applying it to SARS-CoV-2.

The CDC argue that the defining characteristic of airborne vs droplet transmission is the size of the expelled aerosols 6 . The UK guidance followed the CDC aerosol size (≤5µ vs >5µ) definition for both airborne and droplet precautions 1 . The CDC 6 referenced the aerosol size delineation to work published by Duguid (1946) 7 . However, that author referred such a finding to Hatch (1942) 8 . Hatch (1942) 8 , without producing data, stated "particles larger than 5µ are primarily removed in the upper tract while fine particles are deposited by settlement in the alveoli." The implication of Hatch's (1942) work was considered of "aetiological significance in the cause of lung infection." 7 There is no mention in either paper of size of the particles being relevant to disease transmission. Duguid (1946) showed that "…nuclei larger than 8µ in diameter usually disappeared within 20 minutes, the nuclei larger than 4µ within 90 minutes and the smaller nuclei [presumably ≤3µ and not ≤5µ] remained airborne for much longer periods". 7 Others argue that the cut-off at >5µ, fails to acknowledge that the size and behaviour of particles follows a continuum which overlaps either side of this cut-off 3 . Ergo, there is an absence of absolute aerosol size delineation to determine airborne or droplet transmission. Also, for any individual patient, critical J o u r n a l P r e -p r o o f factors such as respiratory activity (and its frequency), the number of particles generated and the pathogen load are unknown 3 .

Droplets evaporate rapidly and fall to the ground quickly; but horizontally expelled large droplets travel long distances 9 . These large droplets were carried more than 6m by exhaled air at a velocity of 50m/s for sneezing and 2m/s away for coughing, and 1m/s for breathing 9 . Another recent report demonstrated that coughs and sneezes, are made of up of a "multiphase turbulent gas cloud that entrains ambient air and traps and carries within it droplets with a continuum of droplet sizes" 10 . Could it be that it is the closeness of HCWs to this 'gas cloud' during AGPs -that is the issue rather than the size of particles created?

The theory that aerosol size delineation can determine the respiratory precautions required, appears unsupported by evidence cited in UK and US guidelines. However, despite the theory muddle, there are yet to be published nosocomial outbreak reports which demonstrate cross-transmission resulting from a failure of fully applied droplet precautions. It may be a full face-shield and fluid resistant surgical face mask are sufficient to negate the transmission risk from virus laden aerosols (regardless of size) in many circumstances. That said, the need for critical reconsideration of respiratory transmission is urgently needed.

The author is not seeking to present herself as an expert in respiratory disease transmission. However, in trying to understand the rationale for current recommendations she has found anomalies that appear to question the prevalent paradigm.

J o u r n a l P r e -p r o o f

COVID-19 infection prevention and control guidance

Guidance on the use of respiratory and facial protection equipment

The role of particle size in aerosolised pathogen transmission: A review

Assessing the evidence base for medical procedures which create a higher risk of respiratory infection transmission from patient to healthcare worker

Lessons for COVID-19 immunity from other coronavirus infections

Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings

The size and duration of air-carriage of respiratory droplets and droplet nuclei

Behavior of microscopic particles in the air and in the respiratory system Aerobiology

How far droplets can move in indoor environmentsrevisiting the Wells evaporation-falling curve

Turbulent gas clouds and respiratory pathogen emissions; potential implications for reducing transmission of COVID-19